Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.41 | -0.35% | 115.52 | 471 | 14:00:36 |
From Nov 2023 to Nov 2024
By Denny Jacob
Abbott Laboratories disclosed that the first global procedures have been conducted using its new Volt Pulsed Field Ablation system to treat patients battling common abnormal heart rhythms such as atrial fibrillation.
The healthcare-products manufacturer said over 30 patients were treated in Australia as part of its clinical study evaluating the safety and effectiveness of its Volt PFA system. The company expects approval for its U.S. clinical trial for the system in the first half of this year.
Abbott said patients requiring a cardiac ablation procedure to treat conditions like atrial fibrillation received radiofrequency ablation, which uses heat to destroy tissue responsible for erratic heart signals, or cryogenic ablation, which freezes tissue. The company's system uses high-energy electrical impulses to destroy the cells causing abnormal heart rhythms, rather than heat or extreme cold, which it said can reduce the risk of damaging adjacent tissue in patients with complex disease or anatomy.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 18, 2024 09:33 ET (14:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
